Abstract: The present invention relates to a method and compositions for the treatment of age-related macular degeneration (AMD), in particular dry-AMD, specifically geographic atrophy (GA) or advanced dry-AMD. Specifically, the invention relates to an inner-blood-retinal-barrier (iBRB) or blood-brain-barrier (BBB) tight junction protein and/or a circadian clock protein for use in the prevention and/or treatment of age-related macular degeneration.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
March 15, 2022
Assignee:
The Provost, Fellows, Foundation Scholars & The Other Members Of Board, of he College of the Holy & Undiv. Trinity of Queen El
Inventors:
Matthew Campbell, Sarah Doyle, Natalie Hudson, Lucia Clekova
Abstract: Modified peptides based on C-terminal PDZ binding domains of PTEN and PHLPP, or PDK1 interacting fragment of PKN2 are described as are methods of using the modified peptides for blocking the activity of PTEN, PHLPP and PKN2 and treating sudden cardiac arrest. A method for guiding treatment of cardiac arrest based on sorbitol or taurine levels is also provided.
Type:
Grant
Filed:
June 8, 2020
Date of Patent:
March 1, 2022
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Terry Vanden Hoek, Xiangdong Zhu, Jing Li
Abstract: The present invention relates to novel peptides, composition comprising such peptides including nutritional supplements and methods for inducing satiation and satiety, for weight management and preventing or reducing the incidence of obesity, or for preventing or reducing cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and/or diabetes.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
March 1, 2022
Assignee:
DIET4LIFE APS
Inventors:
Jan Stagsted, Jiehui Zhou, Randi Jessen, Johan Palmfeldt, Erik Torngaard Hansen
Abstract: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
February 15, 2022
Assignee:
ZYMEWORKS INC.
Inventors:
Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, Mario Sanches, Gordon Yiu Kon Ng
Abstract: A sterile, ready-to-use, flowable haemostatic composition comprises a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen binding peptides immobilised to the carrier; a biocompatible liquid; and particles of biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid. Such compositions may be used for the control of bleeding, especially in surgical procedures.
Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
February 15, 2022
Assignee:
Korea Institute of Science and Technology
Inventors:
Sun Hwa Kim, Ick Chan Kwon, In-San Kim, Kwangmeyung Kim, Yoosoo Yang, Young-Ji Ko
Abstract: The present invention provides an oral care composition comprising: (a) a dipeptide of the formula Xaa1-Xaa2 or Xaa2-Xaa1; wherein Xaa1 is an amino acid with a polar uncharged side chain; and Xaa2 is selected from an amino acid with a hydrophobic side chain, an amino acid with a polar uncharged side chain, and proline; or (b) a dipeptide of the formula Xaa3-Xaa4 or Xaa4-Xaa3; wherein Xaa3 is an amino acid with a hydrophobic side chain; and Xaa4 is selected from an amino acid with a hydrophobic side chain and an amino acid with a charged side chain.
Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 2.
Type:
Grant
Filed:
January 9, 2017
Date of Patent:
January 25, 2022
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
Abstract: In some aspects, the present disclosure provides compositions and methods for treating disease, e.g., inflammatory disease. Compositions herein comprise one or more polypeptide fragments of proopiomelanocortin or variants thereof. The one of more polypeptide fragments of proopiomelanocortin or variants thereof may be linked by a linker, e.g., a peptide linker, to form a fusion polypeptide.
Abstract: The present disclosure relates to HAPLN1 protein of an aged individual. The HAPLN1 protein exhibits reduced expression with aging, and when administered, its effect in alleviating and reversing skin aging including wrinkles is excellent. Therefore, by exploiting the difference in expression, provided are a biomarker composition for measuring skin aging, capable of diagnosing skin aging; a kit; and a method of screening for skin aging alleviating agents, comprising detecting the expression level of HAPLN1 protein or HAPLN1 gene. In addition, provided are a pharmaceutical composition, cosmetic composition, or health functional food for preventing or alleviating skin aging, and a cosmetic composition or health functional food for alleviating wrinkles, each containing any one or more selected from the group consisting of HAPLN1 protein, a gene encoding the same, and an effective agent for promoting the expression or activating the functions of HAPLN1 protein or gene.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
December 21, 2021
Assignee:
HAPLNSCIENCE INC.
Inventors:
Dae Kyong Kim, Zhicheng Fu, Moon Jung Back
Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
December 21, 2021
Assignee:
Cornell University
Inventors:
Gang Lin, Carl Nathan, Pradeep K. Singh
Abstract: Compositions for and methods of preventing, reversing or treating viral infection-induced organ failure provided. The compositions are also suitable for treating and/or preventing COVID-19 and influenza. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 may also be administered as a composition that expresses and releases MG53 after in vivo administration of said composition to a subject.
Type:
Grant
Filed:
February 25, 2021
Date of Patent:
December 14, 2021
Assignee:
OHIO STATE INNOVATION FOUNDATION
Inventors:
Jianjie Ma, Jacob S. Yount, Matthew A. Sermersheim, Adam D. Kenney, Xinyu Zhou, Bryan A. Whitson, Nahush A. Mokadam, Tao Tan, Chuanxi Cai
Abstract: The present invention provides a method for preparing S-Bz-MAG3 as a precursor of contrast media. Thioglycolic acid and benzoyl chloride are taken for the thiol protection reaction. Next, N,N?-dicyclohexylcarbodiimide and N-hydroxysuccinimide are converted to corresponding ester compounds. The corresponding ester compounds then react with triglycine by amide bonding reaction. The product of the reaction is recrystallized using acetone, filtered, and finally flushed using flushing agent to give the final product. This is a bifunctional chelator and can be bridged with 99mTc and 186/188Re effectively and applied to nuclear medicine imaging and tumor radiotherapy. By taking advantage of fewer synthesis steps and ease of operations, complicated separation and purification reactions can be reduced and thus achieving highly productivity of S-Bz-MAG3.
Type:
Grant
Filed:
October 11, 2018
Date of Patent:
November 30, 2021
Assignee:
Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C.
Abstract: Biopolymer compositions comprising antimicrobial peptides (AMPs) for treating infections such as bacterial infections, viral infections, fungal infections, and parasitic infections. The compositions herein may also be used for treating infections associated with antibiotic-resistant bacteria, antifungal-resistant fungi, antiviral-resistant viruses, or for treating biological warfare agents (BWAs) such as Bacillus anthracis and Yersenia pestis. The present invention also provides methods of synthesis of said biopolymer compositions, wherein AMP biopolymers can be synthesized as an artificially engineered protein by genetically fusing an AMP; a protein that behaves similarly to polymer tethers; and a protein as a modifiable material platform that can transform to self-assembled nanoparticles, self-standing films, or adhesives to easily attach tethered AMPs onto any biomaterial surface for various clinical applications.
Type:
Grant
Filed:
January 22, 2019
Date of Patent:
October 26, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: The present invention is related to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising limulus amebocyte lysate (LAL) and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample; wherein the LAL is substantially free of coagulogen. The method also relates to compositions and kits comprising LAL substantially free of coagulogen, and methods of making such.
Type:
Grant
Filed:
August 3, 2017
Date of Patent:
October 26, 2021
Assignee:
Lonza Walkersville, Inc.
Inventors:
Candice Stumbaugh, David S. Herbst, Kenneth E. Nichols, Jr.
Abstract: The present invention pertains to an improved chemical synthesis method for Ahp-cyclodepsipeptides which allows straight forward and easy synthesis of tailor-made Ahp-cyclodepsipeptides. The invention further provides Ahp-cyclodepsipeptides for use as HTRA protease inhibitors and their medical use.
Type:
Grant
Filed:
May 14, 2018
Date of Patent:
October 19, 2021
Assignee:
UNIVERSITÄT DUISBURG-ESSEN
Inventors:
Markus Kaiser, Steffen Köcher, Juliana Rey, Jens Bongard, Michael Ehrmann, Sarah Resch
Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions to treat or prevent an endoplasmic reticulum (ER) stress-mediated kidney disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an ER calcium channel stabilizing agent or an ER stress modulating agent (e.g., mesencephalic astrocyte-derived neurotrophic factor (MANF), compound K201).
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
September 28, 2021
Assignee:
Washington University
Inventors:
Ying Chen, Fumihiko Urano, Yeawon Kim, Sun-Ji Park
Abstract: The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.
Type:
Grant
Filed:
December 7, 2017
Date of Patent:
September 21, 2021
Assignee:
RA PHARMACEUTICALS, INC.
Inventors:
Alonso Ricardo, Steven James DeMarco, Sylvia Tobe, Michelle Denise Hoarty, Robert Paul Hammer, Douglas A. Treco, Kathleen Seyb, Vaishnavi Rajagopal, Guo-Qing Tang, Douangsone D. Vadysirisack, Ramin Farzaneh-Far